

行政院國家科學委員會專題研究計畫 期中進度報告

胃癌血管新生之機制：介白質-6 與血管內皮生長因子之角色 及相互作用(1/2)

計畫類別：個別型計畫

計畫編號：NSC92-2314-B-002-133-

執行期間：92 年 08 月 01 日至 93 年 07 月 31 日

執行單位：國立臺灣大學醫學院一般醫學科

計畫主持人：吳明賢

共同主持人：郭明良

報告類型：精簡報告

處理方式：本計畫可公開查詢

中 華 民 國 93 年 5 月 25 日

行政院國家科學委員會專題研究計畫成果報告

胃癌血管新生之機制：介白質-6與血管內皮生長因子之角色及相互作用 (1/2)

The mechanism of angiogenesis in gastric carcinoma: the role and interaction between interleukin-6 and vascular endothelial growth factor (1/2)

計畫類別： ☒ 個別型計畫 ☐ 整合型計畫

計畫編號： NSC92-2314-B-002-133

執行期間： 92年 8月 1日至 93年 7月 31日

整合型計畫：吳明賢醫師

處理方式： ☐ 可立即對外提供參考
 ☒ 一年後可對外提供參考
 ☐ 兩年後可對外提供參考
(必要時，本會得展延發表時限)

執行單位：台大醫學院一般醫學科

中華民國 93 年 5 月 26 日

中文摘要

血管新生(angiogenesis)目前熟知為惡性腫瘤的生長、侵犯、及轉移所必須。過去研究發現胃癌腫瘤血管新生與其病程、淋巴及遠處轉移、手術後再發等有相關性。許多血管新生因子及抗血管新生因子已被發現在此血管新生過程很重要。在這許多的血管新生因子中，血管內皮生長因子(vascular endothelial growth factor, VEGF)在胃癌生成之血管新生居樞紐地位。然而，目前尚無細胞外分子證實在胃癌可以調控增加血管內皮生長因子。介白質-6(Interleukin-6, IL-6)在幽門螺旋桿菌胃炎中表現增加，也曾被報告與胃癌疾病狀態有關，但其機制仍不清楚。我們較早之研究發現胃癌病人血清之介白質-6 與血管內皮生長因子有正相關，此結果暗示介白質-6 可能透過與血管內皮生長因子產生之互動進而在胃癌之血管新生扮演某個角色。因此吾人假設：介白質-6 經由誘導產生血管內皮生長因子而刺激胃癌之腫瘤血管新生。於此計劃中，我們將先藉由臨床研究驗證介白質-6、生血管內皮生長因子、腫瘤血管之相關性，再藉由胃癌細胞株實驗性研究探討此三者之關係。

本計劃的第一年，我們著重在驗證介白質-6、生血管內皮生長因子、腫瘤血管在胃癌之臨床相關性。胃癌樣本收集自臺大醫院之外科手術檢體，該樣本以免疫組織化學染色(immunohistochemical staining)染介白質-6、生血管內皮生長因子、及腫瘤血管。免疫組織化學染色活性分級後根據不同臨床病理特性加以分析，我們發現介白質-6、生血管內皮生長因子、腫瘤血管在不同次分組胃癌有正相關性 (Table 1, 2)。而這實驗性研究中，我們以 ELISA 評估不同劑量及時間之介白質-6 刺激在不同胃癌細胞株中所產生之血管內皮生長因子 (Figure 2a,b)。三種訊息傳遞路徑：JAK/STAT、Raf/MAPK、及 PI3K/Akt 中介白質-6 刺激之細胞訊息。因此我們利用 firefly luciferase reporter gene assay 研究哪一條訊息傳遞路徑負責傳導介白質-6 刺激活化生血管內皮生長因子之啟動子 (Figure 3)。在研究介白質-6 對 *in vitro* 血管新生的影響，我們利用介白質-6 刺激胃癌細胞後收集之培養液來培養人類臍靜脈內皮細胞，評估其生長及形成管狀結構之效應 (Figure 4, 5a-d)。在研究介白質-6 對 *in vivo* 血管新生的影響，我們利用 Matrigel plug assay 來評估。Matrigel 與介白質-6 刺激胃癌細胞後收集之培養液混合後注射於小鼠皮下，收取此 Matrigel plug 後觀察其巨觀差異，並測定其血紅素密度以代表腫瘤血管密度 (Figure 6a-e)。我

們的結果顯示介白質-6 可以刺激胃癌細胞株產生血管內皮生長因子，並進一步證實其訊息傳遞係經由 JAK/STAT 路徑。同時亦證明介白質-6 可以增加胃癌的 in vitro 及 in vivo 血管新生。以上研究成果已於最近發表（J Biomed Sci 2004;11:517-527, DOI: 10.1159/000077902）。

在本計劃的第二年，我們將繼續收集胃癌病人及健康對照，抽取白血球 DNA，分析兩組介白質-6 基因單核苷酸多型性之差異性。並將胃癌病人之介白質-6 基因單核苷酸多型性之差異性與血管內皮生長因子表現做相關性分析，根據不同臨床及病理特性加以對照，以探討訴主敏感性角色。

關鍵詞：血管新生，血管內皮生長因子，介白質-6，胃癌，基因單核苷酸多型性

Abstract

Angiogenesis is currently well known to be essential for the growth, invasion, and metastasis in malignancies. Earlier studies showed that tumor angiogenesis of gastric carcinoma (GC) correlates with disease stage, lymphatic and distant metastases, recurrence after operation. A wide variety of angiogenic and antiangiogenic factors have been found to be important in this angiogenic process. Among the vast of angiogenic factors, vascular endothelial growth factor (VEGF) is reported to be pivotal for angiogenesis in gastric carcinogenesis. However, no extracellular molecule has yet been documented as being capable of up-regulating VEGF in GC. Interleukin-6 (IL-6) increases in *Helicobacter pylori* gastritis and is reported to be associated with the disease status of GC, but the mechanism underlying this association remains unclear. Our earlier research has found a positive association between the serum levels of IL-6 and VEGF in GC patients, which suggested that IL-6 might play a role for angiogenesis in GC via an interaction with VEGF production. Accordingly, we propose a hypothesis that IL-6 simulates tumor angiogenesis in GC via inducing VEGF. In this project, we will verify the association of IL-6, VEGF, and tumor vasculature by the clinical studies on tumor tissues and investigate their relationship by the experimental studies using GC cell lines.

During the first year of this project, we focus on the verification of the clinical association among IL-6, VEGF, and tumor vasculature in GC. GC samples obtained from surgical specimens at National Taiwan University are collected for immunohistochemical examination of IL-6, VEGF, and tumor microvessels. The immunoreactivities will be graded and then analyzed according to the different clinicopathologic characteristics. We found that there was a positive association among IL-6, VEGF, and tumor vasculature in different subsets of GC (Table 1, 2). In the experimental studies, we first assessed the effects of dose and duration of IL-6 simulation on VEGF production in different GC cell lines by ELISA (Figure 2a,b). Three signaling pathways, JAK/STAT, Raf/MAPK, and Akt/PI3K, mediate the cellular signals of IL-6 stimulation. Therefore, we next employed firefly luciferase reporter gene assay to determine the signaling pathway involved in the activation of the promoter of VEGF gene by IL-6 (Figure3). To study the effect of IL-6 on

angiogenesis *in vitro*, the growth and tube formation of human umbilical vein endothelial cells cultured with conditioned media obtained from the GC cells after IL-6 stimulation are to be assessed (Figure 4, 5a-d). In assessment of the effect of IL-6 on angiogenesis *in vivo*, Matrigel plug assay will be used. Matrigel plugs were harvested from mice injected subcutaneously with the mixture of Matrigel and conditioned media for gross examination and determination of hemoglobin densities, which stand for tumor vasculature (Figure 6a-e). We found that IL-6 indeed induced VEGF production in GC cells, which was mediated through JAK/STAT pathway. Meanwhile, we also demonstrated that IL-6 can increase *in vitro* and *in vivo* angiogenesis in GC. The research manuscript has been published (J Biomed Sci 2004;11:517-527, DOI: 10.1159/000077902).

During the second year of this project, we will continue enrolling GC patients and health controls and obtain WBC DNA to compare the single nucleotide polymorphisms (SNPs) of IL-6 between these two groups. We also intend to analyze the relationship between the SNPs of IL-6 and the expression of VEGF, stratified by different clinicopathological characteristics, to investigate the role of host susceptibility.

Keywords: angiogenesis, vascular endothelial growth factor, interleukin-6, gastric carcinoma, single nucleotide polymorphism

結果 : Tables & Figures

Table 1	Table 2
Figure 2a	Figure 2b
Figure 3	Figure 4
Figure 5a	Figure 5b
Figure 5c	Figure 5d
Figure 6a-d	Figure 6e

Table 1. VEGF immunoreactivity and MVD in gastric carcinoma with different IL-6 immunoreactivities





	Total	IL-6 immunoreactivity		p value
		high	low	
Cases	54	42	12	
Age, years	59.9±13.5	62.1±12.5	59.3±13.9	0.539
Gender (M:F)	28:26	20:22	8:4	0.332
VEGF (H:L)	44:10	38:4	6:6	0.005
MVD*	37.8±31.4	42.5±32.0	21.5±23.3	0.040





High = High immunoreactivity of IL-6 (- or +); low = low immunoreactivity of IL-6 (++ or +++); M = male; F = female; H = high immunoreactivity of VEGF; L = low immunoreactivity of VEGF.

Table 2. Relationship between IL-6 and VEGF immunoreactivities in different subsets of gastric carcinoma

	High IL-6 high:low VEGF	Low IL-6 high:low VEGF	p value
Tumor stage			
Advanced	35:3	6:4	0.027*
Early	3:1	0:2	0.400
Lauren's type			
Intestinal type	23:1	4:4	0.009*
Diffuse type	15:3	2:2	0.210
Location			
Non-cardiac	31:4	5:6	0.006*
Cardiac	7:0	1:0	
<i>H. pylori</i>			
Present	23:4	1:4	0.009*
Absent	15:0	5:2	0.091

High:low VEGF = High/low immunoreactivity of VEGF.
* p < 0.05 by Fisher's exact test.





參考文獻

1. Fuchs CS, Mayer RJ. Gastric carcinoma. *N Engl J Med* 333:32-41;1995.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. *Cell* 86:353-364;1996.
3. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. *N Engl J Med* 333:1757-1763;1995.
4. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. *Nature* 407:249-257;2000.
5. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. *Science* 284:808-812;1999.
6. Ferrara N. Timeline: VEGF and the quest for tumour angiogenesis factors. *Nat Rev Cancer* 2:795-803;2002.
7. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. *Nature* 407:242-248;2000.
8. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. *Science* 246:1306-1309;1989.
9. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT. Vascular permeability factor, an endothelial cell mitogen related to PDGF. *Science* 246:1309-1312;1989.
10. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. *Cancer Res* 55:3964-3968;1995.
11. Linderholm B, Grankvist K, Wilking N, Johansson M, Tavelin B, Henriksson R. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive

breast carcinoma after adjuvant treatment. J Clin Oncol 18:1423-1431;2000.

12. Suzuki K, Hayashi N, Miyamoto Y, Yamamoto M, Ohkawa K, Ito Y, Sasaki Y, Yamaguchi Y, Nakase H, Noda K, Enomoto N, Arai K, Yamada Y, Yoshihara H, Tujimura T, Kawano K, Yoshikawa K, Kamada T. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res 56:3004-3009;1996.
13. Yuan A, Yu CJ, Luh KT, Kuo SH, Lee YC, Yang PC. Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. J Clin Oncol 20:900-910;2002.
14. Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol 18:2046-2052;2000.
15. Guidi AJ, Abu-Jawdeh G, Berse B, Jackman RW, Tognazzi K, Dvorak HF, Brown LF. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 87:1237-1245;1995.
16. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153:1249-1256;1998.
17. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 143:1255-1262;1993.
18. Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM, Serve H, Berdel WE, Kienast J. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95:2630-2636;2000.
19. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77:858-863;1996.

20. Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T. Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. *J Clin Oncol* 15:826-832;1997.
21. Tao HQ, Lin YZ, Wang RN. Significance of vascular endothelial growth factor messenger RNA expression in gastric cancer. *World J Gastroenterol* 4:10-13;1998.
22. Saito H, Tsujitani S, Kondo A, Ikeguchi M, Maeta M, Kaibara N. Expression of vascular endothelial growth factor correlates with hematogenous recurrence in gastric carcinoma. *Surgery* 125:195-201;1999.
23. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. *J Mol Med* 77:527-543;1999.
24. Tsuzuki Y, Fukumura D, Oosthuyse B, Koike C, Carmeliet P, Jain RK. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1 α --> hypoxia response element--> VEGF cascade differentially regulates vascular response and growth rate in tumors. *Cancer Res* 60:6248-6252;2000.
25. Renner U, Lohrer P, Schaaf L, Feirer M, Schmitt K, Onofri C, Arzt E, Stalla GK. Transforming Growth Factor-beta Stimulates Vascular Endothelial Growth Factor Production by Folliculostellate Pituitary Cells. *Endocrinology* 143:3759-3765;2002.
26. Warren RS, Yuan H, Matli MR, Ferrara N, Donner DB. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. *J Biol Chem* 271:29483-29488;1996.
27. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. *Mol Biol Cell* 4:121-133;1993.
28. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. *Biochem J* 334 (Pt 2):297-314;1998.
29. Wu CW, Wang SR, Chao MF, Wu TC, Lui WY, P'Eng F K, Chi CW. Serum

interleukin-6 levels reflect disease status of gastric cancer. *Am J Gastroenterol* 91:1417-1422;1996.

30. Wei LH, Kuo ML, Chen CA, Cheng WF, Cheng SP, Hsieh FJ, Hsieh CY. Interleukin-6 in cervical cancer: the relationship with vascular endothelial growth factor. *Gynecol Oncol* 82:49-56;2001.
31. Hatzi E, Murphy C, Zoepfel A, Rasmussen H, Morbidelli L, Ahorn H, Kunisada K, Tontsch U, Klenk M, Yamauchi-Takahara K, Ziche M, Rofstad EK, Schweigerer L, Fotsis T. N-myc oncogene overexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth. *Oncogene* 21:3552-3561;2002.
32. Huang SP, Wu MS, Wang HP, Yang CS, Kuo ML, Lin JT. Correlation between serum levels of interleukin-6 and vascular endothelial growth factor in gastric carcinoma. *J Gastroenterol Hepatol* 17:1165-1169;2002.
33. Kajitani T. The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. *Jpn J Surg* 11:127-139;1981.
34. Laurén P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at histoclinical classification. *Acta Path Microbiol Scand* 64:31–49;1965.
35. Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch G, Jr., Klocker H, Bartsch G, Culig Z. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. *J Pathol* 191:239-244;2000.
36. Huang SP, Wu MS, Shun CT, Wang HP, Lin JT. Tumor angiogenesis increases with nuclear p53 accumulation in gastric carcinoma. *Hepatogastroenterology* 49:1453-1456;2002.
37. Fackler MJ, Civin CI, Sutherland DR, Baker MA, May WS. Activated protein kinase C directly phosphorylates the CD34 antigen on hematopoietic cells. *J Biol Chem* 265:11056-11061;1990.
38. Li L, Yang G, Ebara S, Satoh T, Nasu Y, Timme TL, Ren C, Wang J, Tahir SA, Thompson TC. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. *Cancer Res* 61:4386-4392;2001.

39. Maity A, Pore N, Lee J, Solomon D, O'Rourke DM. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia. *Cancer Res* 60:5879-5886;2000.
40. Kubota Y, Kleinman HK, Martin GR, Lawley TJ. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. *J Cell Biol* 107:1589-1598;1988.
41. Juarez JC, Guan X, Shipulina NV, Plunkett ML, Parry GC, Shaw DE, Zhang JC, Rabbani SA, McCrae KR, Mazar AP, Morgan WT, Donate F. Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain. *Cancer Res* 62:5344-5350;2002.
42. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, Pauly RR, Grant DS, Martin GR. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. *Lab Invest* 67:519-528;1992.
43. Crabtree JE, Shallcross TM, Heatley RV, Wyatt JI. Mucosal tumour necrosis factor alpha and interleukin-6 in patients with *Helicobacter pylori* associated gastritis. *Gut* 32:1473-1477;1991.
44. Judd LM, Alderman BM, Howlett M, Shulkes A, Dow C, Moverley J, Grail D, Jenkins BJ, Ernst M, Giraud AS. Gastric cancer development in mice lacking the SHP2 binding site on the IL-6 family co-receptor gp130. *Gastroenterology* 126:196-207;2004.
45. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. *Nat Med* 9:669-676;2003.
46. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. *Blood* 86:1243-1254;1995.
47. Ueda T, Bruchofsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. *J Biol Chem* 277:7076-7085;2002.

48. Chen RH, Chang MC, Su YH, Tsai YT, Kuo ML. Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. *J Biol Chem* 274:23013-23019;1999.
49. Funamoto M, Fujio Y, Kunisada K, Negoro S, Tone E, Osugi T, Hirota H, Izumi M, Yoshizaki K, Walsh K, Kishimoto T, Yamauchi-Takahara K. Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes. *J Biol Chem* 275:10561-10566;2000.
50. Xu L, Fukumura D, Jain RK. Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanism of low pH-induced VEGF. *J Biol Chem* 277:11368-11374;2002.
51. Gao N, Ding M, Zheng JZ, Zhang Z, Leonard SS, Liu KJ, Shi X, Jiang BH. Vanadate-induced expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. *J Biol Chem* 277:31963-31971;2002.
52. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like Growth Factor 1 Induces Hypoxia-inducible Factor 1-mediated Vascular Endothelial Growth Factor Expression, Which is Dependent on MAP Kinase and Phosphatidylinositol 3-Kinase Signaling in Colon Cancer Cells. *J Biol Chem* 277:38205-38211;2002.
53. Wei LH, Kuo ML, Chen CA, Chou CH, Lai KB, Lee CN, Hsieh CY. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. *Oncogene* 22:1517-1527;2003.
54. LeCouter J, Kowalski J, Foster J, Hass P, Zhang Z, Dillard-Telm L, Frantz G, Rangell L, DeGuzman L, Keller GA, Peale F, Gurney A, Hillan KJ, Ferrara N. Identification of an angiogenic mitogen selective for endocrine gland endothelium. *Nature* 412:877-884;2001.
55. Kim YM, Lee YM, Kim HS, Kim JD, Choi Y, Kim KW, Lee SY, Kwon YG. TNF-related activation-induced cytokine (TRANCE) induces angiogenesis through the activation of Src and phospholipase C (PLC) in human

endothelial cells. J Biol Chem 277:6799-6805;2002.

56. Shih SC, Ju M, Liu N, Mo JR, Ney JJ, Smith LE. Transforming growth factor beta1 induction of vascular endothelial growth factor receptor 1: mechanism of pericyte-induced vascular survival in vivo. Proc Natl Acad Sci U S A 100:15859-15864;2003.
57. Kitadai Y, Takahashi Y, Haruma K, Naka K, Sumii K, Yokozaki H, Yasui W, Mukaida N, Ohmoto Y, Kajiyama G, Fidler IJ, Tahara E. Transfection of interleukin-8 increases angiogenesis and tumorigenesis of human gastric carcinoma cells in nude mice. Br J Cancer 81:647-653;1999.
58. Salven P, Hattori K, Heissig B, Rafii S. Interleukin-1alpha promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion. Faseb J 16:1471-1473;2002.
59. Jung YD, Liu W, Reinmuth N, Ahmad SA, Fan F, Gallick GE, Ellis LM. Vascular endothelial growth factor is upregulated by interleukin-1 beta in human vascular smooth muscle cells via the P38 mitogen-activated protein kinase pathway. Angiogenesis 4:155-162;2001.
60. Kohno T, Mizukami H, Suzuki M, Saga Y, Takei Y, Shimpo M, Matsushita T, Okada T, Hanazono Y, Kume A, Sato I, Ozawa K. Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. Cancer Res 63:5091-5094;2003.
61. Hsu CH, Yeh KH, Chen LT, Liu JM, Jan CM, Lin JT, Chen YC, Cheng AL. Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers. An effective and low-toxic regimen for patients with poor general condition. Oncology 54:275-280;1997..
62. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727-739;2002

已發表或投稿之論文